Gastric cancer is the cancer originating in the esophagus, esophagogastric junction and stomach.
Most of gastric cancers are adenocarcinomas, subdivided according to histological appearances into diffuse (undifferentiated) and intestinal (well differentiated) types.
It is the 4th most common cancer and the 2nd most common cause of cancer-related deaths worldwide.
Most common sites of gastric cancer are the proximal lesser curvature, cardia and esophagogastric junction.
Fifth most common cancer and third most common cause of cancer-related deaths worldwide
In Japan, this is the most common type of cancer in men
Most common sites of gastric cancer are the proximal lesser curvature, cardia and esophagogastric junction
Cancers originating in the esophagus, esophagogastric junction and stomach
Most of gastric cancers (over 95%) are adenocarcinomas, subdivided according to histological appearances into diffuse (undifferentiated) and intestinal (well-differentiated) types (Lauren classification)
Signs and Symptoms
Early stage gastric cancer rarely causes symptoms
Most commonly diagnosed at an advanced stage
Dyspepsia is the early stage symptom
Advanced stage signs and symptoms include:
Vague abdominal discomfort, usually above the navel
A sense of fullness in the upper abdomen after eating a small meal (early satiety)
Heartburn or indigestion
Nausea and vomiting
Swelling or fluid build-up in the abdomen
Old age (>50 years old)
Helicobacter pylori infection
Usually the major cause
Previous gastric surgery eg partial gastrectomy
Menetrier’s disease or hypertrophic gastropathy
Diet that has large amounts of smoked foods, salted fish and meat and pickled vegetables
Nitrates and nitrites on these foods have shown to produce bacteria that causes cancer
At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.